HealthNotableSingle-source
5.3
Hanmi Pharm enters 3.2 trillion won licensing agreement with Genentech for obesity drug candidate
Yonhap ENLO·KR · CH·about 16 hours ago
HealthSingle-sourceMediumDeveloping
5.2
Novo Nordisk and Eli Lilly pivot R&D toward next-generation obesity therapeutics
Novo Nordisk and Eli Lilly are expanding their drug development pipelines to target novel hormonal pathways for obesity treatment. The initiative aims to improve patient adherence by mitigating the gastrointestinal side effects associated with current GLP-1 receptor agonists.
Score Breakdown
Mosaic Score5.2
Confidence0.9
Significance0.5
Source credibility0.3
Related signals
8 foundHealthNotableSingle-sourceDeveloping
5.2
FTC challenges Amgen patent strategy; Moderna-Merck cancer vaccine progress update
STAT NewsLO·US·about 7 hours ago
HealthSingle-source
2.1
South Korean pharmaceutical majors increase H1 R&D expenditure to over 100 billion won each
Yonhap ENLO·KR·2 days ago
HealthHighSingle-sourceDeveloping
7.3
Moderna and Merck report successful clinical outcomes for mRNA cancer vaccine
STAT NewsLO·US·about 11 hours ago
HealthNotableConfirmed
6.9
Anvisa approves second generic semaglutide in Brazil
InfoMoney·BR·about 7 hours ago
HealthNotableEmergingDeveloping
6.0
Potential access disparities for Moderna-Merck cancer vaccines in European markets
La Tribune·US · FR·2 days ago
HealthNotableConfirmedDeveloping
5.9
Eli Lilly launches oral weight-loss drug Foundayo in UK market
Valor Econômico·GB·about 8 hours ago
HealthNotableConfirmed
5.9
Anvisa cancels registration of Duchenne muscular dystrophy therapy Elevidys
Poder360·BR·about 7 hours ago